Sellas Life Sciences Newsroom

Sellas Life Sciences Group Inc (NASDAQ:SLS): A Bull Case Theory

Yahoo FinanceSep 19 03:09

Buy Rating Affirmed for SELLAS Life Sciences Amid Strong Financial Position and Promising Clinical Trials

TipRanksAug 15 23:45 · Ratings

Express News | Sellas Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update

BreakingsAug 14 04:10

Express News | Sellas Life Sciences Q2 Basic EPS USD -0.13

BreakingsAug 14 04:10

Express News | Sellas Life Sciences Q2 Net Income USD -7.47 Million

BreakingsAug 14 04:10

Express News | Sellas Life Sciences Q2 Operating Income USD -7.621 Million

BreakingsAug 14 04:10

Sellas Life Sciences | 10-Q: Q2 2024 Earnings Report

SECAug 14 04:02 · Announcements

Express News | Sellas Receives EMA Orphan Drug Designation for Sls009 for Treatment of Peripheral T-Cell Lymphomas

BreakingsAug 6 20:45

SELLAS Life Sciences Enters $21M Securities Purchase Agreement With Institutional Investor; Direct Offering Includes 15.8M Shares And Warrants Priced At $1.325 Per Share, Exercisable At $1.20; Expected To Close On August 1, 2024

BenzingaJul 31 20:33

Express News | Sellas Life Sciences Announces $21.0 Million Registered Direct Offering Priced at a Premium to Market

BreakingsJul 31 20:30

Express News | Sellas Announces U.S. FDA Rare Pediatric Disease Designation (Rpdd) Granted to Sls009 for the Treatment of Pediatric Acute Myeloid Leukemia

BreakingsJul 16 21:05

SELLAS' SLS009 Granted Orphan Drug Designation by EMA for Acute Myeloid Leukemia Treatment

Seeking AlphaJul 8 21:46

Sellas Life Sciences' Potential Myeloid Leukemia Therapy Receives EU Orphan Drug Designation

MT NewswiresJul 8 21:24

SELLAS Life Sciences Granted Orphan Drug Designation By European Commission For SLS009, A Novel CDK9 Inhibitor For Treating Acute Myeloid Leukemia

BenzingaJul 8 20:46

Express News | Sellas Life Sciences Group Inc: On Track to Share Further Data Around Sls009 in Q3 of This Year

BreakingsJul 8 20:45

Express News | Sellas Receives European Medicines Agency Orphan Drug Designation for Sls009 for the Treatment of Acute Myeloid Leukemia

BreakingsJul 8 20:45

SELLAS Life Sciences Shares Are Trading Higher After the Company Was Granted FDA Rare Pediatric Disease Designation for Its SLS009 CDK9 Inhibitor for the Treatment of Pediatric Acute Lymphoblastic Leukemia, Making It Eligible for a Priority Review...

BenzingaJun 24 21:22

Express News | Sellas Announces U.S. FDA Rare Pediatric Disease Designation Granted to Sls009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia

BreakingsJun 24 21:05

Solaris Resources Analyst Ratings

BenzingaJun 21 23:13

Sellas Falls 17% Amid Phase 3 Study Update for Galinpepimut-S

Seeking AlphaJun 18 03:07